Ethylenediamine

Ethylenediamine

SCHEMBL731611

NCCN.O=C(O)c1ccc(O)c(C(C(=O)O)c2cc(C(=O)O)ccc2O)c1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Ethylenediamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
MAPT P10636 4/20 0.48
PTGS2 P35354 2/20 0.48
POLB P06746 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA4 P22748 2/20 0.48
CA6 P23280 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
GAA P10253 2/20 0.48
KDM5A P29375 2/20 0.42
PTGS1 P23219 1/20 0.42
TDP1 Q9NUW8 3/20 0.41
GRM1 Q13255 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylenediamine SCHEMBL14353963 0.87 KDM4E (0.48) KDM4EMAPTPTGS2POLBL3MBTL1
Ethylenediamine SCHEMBL8671797 0.81 KDM4E (0.46) KDM4EMAPTPTGS2POLBL3MBTL1
SCHEMBL2797912 0.77 KDM4E (0.42) KDM4EMAPTPTGS2POLBL3MBTL1
Ethylenediamine SCHEMBL544736 0.75 TSHR (0.42) KDM4EMAPTPTGS2POLBCA12
Ethylenediamine SCHEMBL5159417 0.74 TSHR (0.41) KDM4EMAPTPTGS2POLBCA12
SCHEMBL30720426 0.73 KDM4E (0.48) KDM4EMAPTPTGS2POLBL3MBTL1
SCHEMBL29120261 0.73 KDM4E (0.48) KDM4EMAPTPTGS2POLBL3MBTL1
SCHEMBL383610 0.73 HSP90AA1 (0.60) KDM4EMAPTPTGS2POLBL3MBTL1
SCHEMBL1446646 0.72 RORC (0.53) KDM4EMAPTPTGS2POLBL3MBTL1
SCHEMBL2797924 0.72 KDM4E (0.47) KDM4EMAPTPTGS2POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3191431-B1 MICRONUTRIENT FERTILIZER SUN CHEMICAL CORP (US) 2023-03-08 EP claimed
US-20170283334-A1 MICRONUTRIENT FERTILIZER SUN CHEMICAL CORPORATION (US) 2017-10-05 US claimed
EP-3191431-A1 MICRONUTRIENT FERTILIZER Sun Chemical Corporation (US) 2017-07-19 EP claimed
WO-2016040564-A1 MICRONUTRIENT FERTILIZER SUN CHEMICAL CORPORATION (US) 2016-03-17 WO claimed
EP-3191431-B1 MICRONUTRIENT FERTILIZER SUN CHEMICAL CORP (US) 2023-03-08 EP disclosed
US-11234931-B2 No-rinse chemical foam containing brimonidine, and use thereof in the treatment of rosacea GALDERMA RESEARCH & DEVELOPMENT (FR) 2022-02-01 US disclosed
US-11160812-B2 No-rinse chemical foam containing clobetasol propionate, and use thereof in the treatment of psoriasis GALDERMA RESEARCH & DEVELOPMENT (FR) 2021-11-02 US disclosed
US-11020348-B2 No-rinse chemical foam containing trifarotene, and use thereof in the treatment of ichthyosis GALDERMA RESEARCH & DEVELOPMENT (FR) 2021-06-01 US disclosed
US-11020347-B2 No-rinse chemical foam containing trifarotene, and use thereof in the treatment of acne GALDERMA RESEARCH & DEVELOPMENT (FR) 2021-06-01 US disclosed
US-10987307-B2 No-rinse chemical foam comprising ivermectin GALDERMA RESEARCH & DEVELOPMENT (FR) 2021-04-27 US disclosed
US-10821076-B2 Self-foaming cleansing composition containing clobetasol propionate, and use thereof in the treatment of psoriasis GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-11-03 US disclosed
US-10407353-B2 Micronutrient fertilizer SUN CHEMICAL CORPORATION (US) 2019-09-10 US disclosed
US-20100160439-A1 DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-24 US disclosed
US-20100143285-A1 Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE. 2010-06-10 US disclosed
EP-2167063-A1 COMPOSITION AND USES OF A RETINOID, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE, IN ACNE Galderma Research & Development (FR) 2010-03-31 EP disclosed
EP-2167062-A1 COMPOSITIONS AND USES COMPRISING A RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE IN ACNE Galderma Research & Development (FR) 2010-03-31 EP disclosed
US-20090247630-A1 DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND AND AT LEAST ONE FILM-FORMING AGENT AND TREATMENT OF KERATINIZATION DISORDERS THEREWITH GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-10-01 US disclosed
WO-2008152064-A1 COMPOSITIONS AND USES COMPRISING A RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE IN ACNE GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed
WO-2008152065-A1 COMPOSITION AND USES OF A RETINOID, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE, IN ACNE GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed
US-20080253986-A1 Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160812-B2 No-rinse chemical foam containing clobetasol propionate, and use thereof in the treatment of psoriasis PRKACA, NOS1, NOS2 KDM4E 2490/4885MAPT 3765/4885PTGS2 389/4885
US-20090247630-A1 DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND AND AT LEAST ONE FILM-FORMING AGENT AND TREATMENT OF KERATINIZATION DISORDERS THEREWITH CUTA, NOTUM, KRT18 KDM4E 4333/4885MAPT 989/4885PTGS2 2319/4885
US-20080253986-A1 Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers CUTA, NACA, PUF60 KDM4E 4695/4885MAPT 534/4885PTGS2 1519/4885
US-20100143285-A1 Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer CUTA, PAOX, HAO2 KDM4E 3878/4885MAPT 406/4885PTGS2 752/4885
US-11234931-B2 No-rinse chemical foam containing brimonidine, and use thereof in the treatment of rosacea NOS1, NOS2, PDE2A KDM4E 3364/4885MAPT 4734/4885PTGS2 419/4885
US-20100160439-A1 DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE RARB, RARA, RARG KDM4E 4729/4885MAPT 3304/4885PTGS2 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.